About LevitasBio
LevitasBio is a company based in San Francisco (United States) founded in 2017 by Lars Steinmetz, Gozde Durmus, and Utkan Demirci. LevitasBio has raised $73.77 million across 4 funding rounds from investors including Novalis LifeSciences, Pavilion Capital Partners and Decheng Capital. LevitasBio offers products and services including LeviCell EOS, LeviCell 1.0, LeviPrep, LeviSelect, and LeviMetrics. LevitasBio operates in a competitive market with competitors including 10X Genomics, Mission Bio, Cellares, LUMICKS and Biolog, among others.
- Headquarter San Francisco, United States
- Founders Lars Steinmetz, Gozde Durmus, Utkan Demirci
- SectorsHealthcare
- Website levitasbio.com
- Social LinkedIn X Facebook
- Total Equity Funding$73.77M (USD)
in 4 rounds
- Latest Funding Round$11.76M (USD), Series C
Mar 2024
- InvestorsNovalis LifeSciences
& 2 more
Products & Services of LevitasBio
LevitasBio offers a comprehensive portfolio of products and services, including LeviCell EOS, LeviCell 1.0, LeviPrep, LeviSelect, and LeviMetrics.
Processes samples to improve cell viability and remove debris.
Elevates research by isolating viable cells from low-quality samples.
Handles primary tissues for better dissociation and integrity.
Enriches specific cells without altering their state.
Analyzes levitated samples using AI-based tools.
Funding Insights of LevitasBio
LevitasBio has successfully raised a total of $73.77M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $11.76 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $73.77M
- Total Rounds 4
- Last Round Series C — $11.76M
- First Round $8M
(Aug 2017)
- Investors Count 3
All 4 funding rounds of LevitasBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $11.76M | Series C | – | – | – |
| Oct 2022 | $35M | Series C | – | Novalis LifeSciences | |
| Jan 2021 | $19.01M | Series B | – | – | – |
| Aug 2017 | $8M | Series A | – | Decheng Capital | – |
3 investors in total: 3 institutional.
Investors in LevitasBio
LevitasBio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Novalis LifeSciences, Pavilion Capital Partners and Decheng Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and advisory services are provided for life sciences. | 2017 | novalislifesciences.com | Portsmouth, USA | |
Growth-stage companies are invested in by this venture capital fund. | – | pavilioncapital.com | New York, United States | |
Venture capital firm focused on life science and technology sectors | – | decheng.com | Shanghai, China |
Investor details for LevitasBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of LevitasBio
16 people are tracked at LevitasBio (6 in leadership, 6 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Lars Steinmetz | Co-Founder | Leadership |
Gozde Durmus | Co-Founder | Leadership |
Utkan Demirci | Co-Founder | Leadership |
Martin Pieprzyk | CEO | Leadership |
Suzanne Weaver | Senior Director, System Development | Leadership |
Geoff Facer | Chief Technology Officer | Leadership |
Victor Tong | Board Member | Board & advisors |
Phillips Huang | Observer | Board & advisors |
Paul Meister | Observer | Board & advisors |
Steve Tablak | Independent Board Member | Board & advisors |
Sandra Gardiner | Board Member | Board & advisors |
Greg Herrema | Advisor | Board & advisors |
Mar Margalef Catala | Field Application Scientist And R&d Scientist | Team |
Kevin Travers | SVP, R&D | Team |
Steven Collier | General Counsel | Team |
Dominique Remy-Renou | SVP, Global Commercial Operations | Team |
Complete people profiles for LevitasBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of LevitasBio
3 dated milestones of LevitasBio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded LevitasBio is founded.
- Funding First funding round of $8.0M.
- Funding Latest funding round, Series C, of $11.8M.
Competitors of LevitasBio
LevitasBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Cellares, LUMICKS and Biolog, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| cellares.com | 2019 | San Francisco, United States | $355M | – | Medical devices for cell-based therapy manufacturing are produced. | |
| lumicks.com | 2014 | Amsterdam, Netherlands | $93.38M | – | Optical tweezers instruments for single-molecule analysis are manufactured. | |
| biolog.com | 1984 | Hayward, United States | $33.62M | 27 | Cell-based phenotyping technologies and assays are provided for microbial analysis. | |
| xcellbio.com | 2012 | San Francisco, United States | $40.9M | 11 | Cell culture analysis devices for cancer research are developed. | |
| atrandi.com | 2016 | Vilnius, Lithuania | $31.01M | – | Microfluidic solutions for life sciences and single-cell analysis are developed. | |
| rebusbio.com | 2006 | Santa Clara, United States | $20M | – | An imaging system for single-cell gene analysis is developed. |
Detailed competitors of LevitasBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of LevitasBio
The website of LevitasBio (levitasbio.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 11.9% vs previous month
Latest news on Levitasbio
Complete news archive for LevitasBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to LevitasBio
10 companies that operate in the same segment as LevitasBio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about LevitasBio
LevitasBio was founded in 2017.
LevitasBio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Martin Pieprzyk is the current CEO of LevitasBio.
LevitasBio is a funded company, having raised a total of $73.77M across 4 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Aug 2017.
Founded in 2017 and based in San Francisco, United States, LevitasBio operates in the biotechnology sector. A single-cell imaging and profiling platform, known as the levitation image cytometry platform, is being developed using magnetic levitation technology. This label-free method for cell analysis is intended for applications in therapeutics, diagnostics, and research. The platform enables universal cell profiling without traditional labeling techniques.
LevitasBio's top competitors include 10X Genomics, Mission Bio and Cellares.
LevitasBio offers LeviCell EOS, LeviCell 1.0, LeviPrep, LeviSelect, and LeviMetrics.
LevitasBio has 3 investors. Key investors include Novalis LifeSciences, Pavilion Capital Partners, and Decheng Capital.